Study of Atomoxetine in the Prevention of Vasovagal Syncope

PHASE3RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
Vasovagal Syncope
Interventions
DRUG

Atomoxetine Hydrochloride

Atomoxetine 40 mg PO BID (morning and late afternoon) Dosing will start at 40 mg daily for 3 days1 week, followed by a forced titration to 40 mg BID, as per the FDA label for atomoxetine

DRUG

Placebo

Placebo Comparator: Placebo Matching placebo will be identical in appearance to the active treatment pill. BID (morning and late afternoon)

Trial Locations (1)

T2N 1N4

RECRUITING

University of Calgary, Calgary

All Listed Sponsors
lead

University of Calgary

OTHER